HCW Biologics Reveals Data for TCE Program Utilizing TRBC Platform
T-Cell Engager Program Announcement: HCW Biologics presented data on their second-generation T-Cell Engager (TCE) program at the SITC 40th Annual Meeting, showcasing their novel TRBC platform technology.
Preclinical Study Results: The lead TCE product candidate, HCW11-018b, demonstrated significant efficacy in preclinical studies, shrinking established tumors in xenograft models and achieving 100% survival in treated mice compared to untreated ones.
Potential Applications: The company believes that their tetra-valent TCEs could not only enhance healthspan for patients with solid tumors, particularly pancreatic cancer and glioblastoma, but also expand treatment options for autoimmune diseases and quality-of-life conditions.
Leadership Statement: Dr. Hing C. Wong, CEO of HCW Biologics, emphasized the promising results of their research and the potential for broader therapeutic applications beyond cancer treatment.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on HCWB
About HCWB
About the author
HCW Biologics Inc. (NASDAQ: HCWB) Engages in Virtual Investor "What This Means" Discussion
Company Overview: HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to combat age-related diseases and chronic inflammation, utilizing their TRBC drug discovery platform.
Product Candidate: The company's lead product, HCW11-040, is a second-generation immune checkpoint inhibitor that combines pembrolizumab with interleukin-7, interleukin-15, and TGF-β receptor components, showing promise in expanding exhausted T cells without side effects.
Upcoming Presentation: HCW Biologics will present data on HCW11-040 at the 40th annual meeting of the Society for Immunotherapy of Cancer (SITC) on November 8, 2025, highlighting its potential as a novel tetra-specific immunotherapeutic.
Forward-Looking Statements: The company has issued forward-looking statements regarding the efficacy of its pembrolizumab-based TRBC fusion molecules, acknowledging the inherent risks and uncertainties in achieving anticipated results.
HCW Biologics Scientists to Showcase Three Posters at the 40th Annual Society for Immunotherapy of Cancer Meeting
Company Overview: HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies targeting chronic inflammation and related diseases, with a proprietary TRBC platform for creating various immunotherapeutic compounds.
Upcoming Presentations: The company will present three posters at the 40th Annual Meeting of the Society for Immunotherapy of Cancer from November 5 to 9, 2025, showcasing their lead drug candidates and their potential applications in cancer therapy.